Phase 2 Cardiomyopathy Trial, Recruiting (NCT07692256)

Phase 2 Cardiomyopathy Trial, Recruiting NCT07692256 Sponsor: Ain Shams University Condition: Cardiomyopathy

Printed from Voxsanity (voxsanity.com.au) — NCT07692256 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Cardiomyopathy

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Children and young people aged 1 month to 18 years old.
People who have been diagnosed with heart failure, confirmed by heart ultrasound showing the heart is not pumping or filling properly, along with signs of fluid build-up or poor blood flow.
People whose heart failure is classified as severe (Ross Class III or IV), or who have a blood marker level (BNP) above 300 pg/mL that indicates significant heart stress.

Who may not be able to join:

Children who have chronic kidney failure.
People who currently have a urinary tract infection (a bladder or kidney infection).
People whose kidneys are not working well enough, specifically where the kidney filtration rate (a measure of how well the kidneys clean the blood) is below 60 mL/minute/1.73 m².
People who have a medical reason they cannot take the study drug empagliflozin, including very poor kidney function (filtration rate below 30 mL/minute/1.73 m²) or a known allergic reaction to empagliflozin, such as severe swelling (angioedema).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +0021223333236

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07692256

Sponsor: Ain Shams University

Phase: Phase 2

Status: Recruiting

Condition: Cardiomyopathy

Trial contact: +0021223333236

More information: https://clinicaltrials.gov/study/NCT07692256

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Children and young people aged 1 month to 18 years old.
People who have been diagnosed with heart failure, confirmed by heart ultrasound showing the heart is not pumping or filling properly, along with signs of fluid build-up or poor blood flow.
People whose heart failure is classified as severe (Ross Class III or IV), or who have a blood marker level (BNP) above 300 pg/mL that indicates significant heart stress.

Who may not be able to join:

Children who have chronic kidney failure.
People who currently have a urinary tract infection (a bladder or kidney infection).
People whose kidneys are not working well enough, specifically where the kidney filtration rate (a measure of how well the kidneys clean the blood) is below 60 mL/minute/1.73 m².
People who have a medical reason they cannot take the study drug empagliflozin, including very poor kidney function (filtration rate below 30 mL/minute/1.73 m²) or a known allergic reaction to empagliflozin, such as severe swelling (angioedema).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Ain Shams University

Registry

ClinicalTrials.gov

Start date

1 December 2025

Est. completion

1 December 2026

Where this trial is recruiting

🇪🇬 Egypt

Primary endpoints

serum Brain Natriuretic Peptide (BNP) in pg/mL

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov